Table 4.

Significant Pearson Correlations for MRI GLS, GCS, chi square analyses for AT vs NAT (a) and chi square analyses for LGE (b).

(a)
Significant Correlations	Coefficient				P value
All Patients
MRI GLS (continuous) & MRI GCS (continuous)	0.49				0.000
MRI GCS (continuous) & MRI LVEF (continuous)	-0.32				0.001
MRI GCS (continuous) & MRI LVESVI (continuous)	0.22				0.021
MRI GCS (continuous) & MRI LVEDVI (continuous)	0.18				0.06
AT Patients
MRI GLS (continuous) & MRI GCS (continuous)	0.493				0.001
MRI GCS (continuous) & MRI LVEF (continuous)	-0.37				0.003
	AT (N (%)		NAT N (%)		Total N (%)		P value
Abnormal GLS	36 (67.9%)		28 (84.8%)		64 (74.4%)		0.080
Abnormal GCS	21 (33.9%))		13 (24.1%))		34 (28.5%)		0.247
Abnormal LVEDVI	16 (34.8%)		14 (37.8%)		301 (36.1%)		0.773
Abnormal LV mass index	8 (17.4%)		6 (16.2%)		14 (16.9%)		0.887
LGE positivity	8 (13.3%)		14 (29.2%)		22 (20.4%)		0.042
Reduced RVEF by CMR	17 (37.8%)		5 (13.5%)		22 (26.8%)		0.014
AT group	Anthracycline(N (%)		No anthracycline N (%)		Total N (%)		P value
Abnormal GLS	32 (74.4%%)		4 (40%)		36 (67.9%)		0.036
AT group	Her2i (N (%)		No Her2i N (%)		Total N (%)		P value
Abnormal GLS	14 (58.3%)		22 (75.9%)		36 (67.9%)		0.174
(b)
	LGE positive		LGE negative		Total		P
All patients
Abnormal GLS	16 (94.1%)		48 (69.6%)		64 (74.4%)		0.038
Abnormal GCS	11 (61.1%)		23 (29.1%)		34 (35.1%)		0.010
Increased LV mass index	6 (37.5%)		2 (3%)		8 (9.6%)		0.0001
Increased LVEDVi	5 (31.3%)		23 (34.3%)		28 (33.7%)		0.534
Reduced RVEF	3 (18.8%)		19 (28.8%)		22 (26.8%)		0.416
CAD	10 (45.5%)		14 (16.3%)		24 (22.2%)		0.003
Valvular disease	8 (36.4%)		12 (14%)		20 (18.5%)		0.016
PE/DVT	6 (27.3%)		10 (11.6%)		16 (14.8%)		0.065
Heart failure	8 (36.4%)		17 (20%)		25 (23.4%)		0.106
AT patients
Increased LV mass index	2 (33.3%)		2 (5%)		4 (8.7%)		0.045
Increased LVEDVi	1 (2.5%)		1 (16.7%)		2 (4.3%)		0.088
CAD	4 50%)		5 (9.6%)		9(15%)		0.013
Valvular disease	4 (50%)		5 (9.6%)		9 (15%)		0.013
PE/DVT	3 (37.5%)		5 (9.6%)		8 (13.3%)		0.065